240 related articles for article (PubMed ID: 23532638)
21. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
22. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy.
Wang ZS; Wu LQ; Yi X; Geng C; Li YJ; Yao RY
BMC Cancer; 2013 Jun; 13():306. PubMed ID: 23800357
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
Gao F; Zhu HK; Zhu YB; Shan QN; Ling Q; Wei XY; Xie HY; Zhou L; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):371-7. PubMed ID: 27498576
[TBL] [Abstract][Full Text] [Related]
24. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma.
Karaoğullarindan Ü; Gümürdülü Y; Üsküdar O; Odabaş E; Güler HS; Tozluklu N; Bağir E; Kuran S
Eur J Gastroenterol Hepatol; 2023 Jan; 35(1):89-93. PubMed ID: 36165051
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.
Cui X; Li Z; Gao PJ; Gao J; Zhu JY
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):157-63. PubMed ID: 25865688
[TBL] [Abstract][Full Text] [Related]
27. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
28. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.
Mu H; Lin KX; Zhao H; Xing S; Li C; Liu F; Lu HZ; Zhang Z; Sun YL; Yan XY; Cai JQ; Zhao XH
World J Gastroenterol; 2014 May; 20(19):5826-38. PubMed ID: 24914343
[TBL] [Abstract][Full Text] [Related]
29. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
30. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
31. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
32. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
33. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas.
Yorita K; Ohno A; Nishida T; Kondo K; Ohtomo T; Kataoka H
BMC Res Notes; 2019 Nov; 12(1):741. PubMed ID: 31706332
[TBL] [Abstract][Full Text] [Related]
35. Villin 1 is a predictive factor for the recurrence of high serum alpha-fetoprotein-associated hepatocellular carcinoma after hepatectomy.
Xieraili M; Yasen M; Mogushi K; Obulhasim G; Mayinuer A; Aihara A; Tanaka S; Mizushima H; Tanaka H; Arii S
Cancer Sci; 2012 Aug; 103(8):1493-501. PubMed ID: 22530999
[TBL] [Abstract][Full Text] [Related]
36. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case-control study.
Li Z; Zhao X; Jiang P; Xiao S; Wu G; Chen K; Zhang X; Liu H; Han X; Wang S; Li X
Medicine (Baltimore); 2016 Aug; 95(31):e4224. PubMed ID: 27495026
[TBL] [Abstract][Full Text] [Related]
37. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma.
Shioga T; Kondo R; Ogasawara S; Akiba J; Mizuochi S; Kusano H; Mihara Y; Tanigawa M; Kinjyo Y; Naito Y; Kuromatsu R; Nakashima O; Yano H
Anticancer Res; 2020 Jul; 40(7):4105-4113. PubMed ID: 32620659
[TBL] [Abstract][Full Text] [Related]
39. Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.
Zheng H; Yang Y; Wang MC; Yuan SX; Tian T; Han J; Ni JS; Wang J; Xing H; Zhou WP
Surg Oncol; 2016 Sep; 25(3):171-7. PubMed ID: 27566019
[TBL] [Abstract][Full Text] [Related]
40. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.
Tsuchiya K; Komuta M; Yasui Y; Tamaki N; Hosokawa T; Ueda K; Kuzuya T; Itakura J; Nakanishi H; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Sakamoto M; Izumi N
Oncology; 2011; 80(3-4):278-88. PubMed ID: 21734420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
